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ARTICLE
Collateral sensitivity constrains resistance
evolution of the CTX-M-15 β-lactamase
Carola E.H. Rosenkilde1, Christian Munck1,3, Andreas Porse1, Marius Linkevicius2, Dan I. Andersson 2 &
Morten O.A. Sommer 1
Antibiotic resistance is a major challenge to global public health. Discovery of new antibiotics
is slow and to ensure proper treatment of bacterial infections new strategies are needed. One
way to curb the development of antibiotic resistance is to design drug combinations where
the development of resistance against one drug leads to collateral sensitivity to the other
drug. Here we study collateral sensitivity patterns of the globally distributed extended-
spectrum β-lactamase CTX-M-15, and ﬁnd three non-synonymous mutations with increased
resistance against mecillinam or piperacillin–tazobactam that simultaneously confer full
susceptibility to several cephalosporin drugs. We show in vitro and in mice that a combi-
nation of mecillinam and cefotaxime eliminates both wild-type and resistant CTX-M-15. Our
results indicate that mecillinam and cefotaxime in combination constrain resistance evolution
of CTX-M-15, and illustrate how drug combinations can be rationally designed to limit the
resistance evolution of horizontally transferred genes by exploiting collateral sensitivity
patterns.
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Antibiotics are essential to modern medicine but theintroduction of new antibiotics is inevitably followed bythe emergence of antibiotic-resistant bacteria as a result of
either chromosomal mutations (adaptive evolution) or horizontal
gene transfer (HGT)1–3. The emergence of resistance, in combi-
nation with the limited development of new drugs, has led to a
marked reduction in our ability to treat bacterial infections efﬁ-
ciently4–6. Accordingly, there is a growing interest in using
existing antibiotics to develop treatment strategies that both
eliminate the unwanted bacteria and extend the life span of
existing antibiotics7–9.
One such strategy is antibiotic combination therapy, which can
both increase the bacterial target spectrum to include resistant
variants and prevent emergence of resistance. Combination
therapy has been successfully applied against infections since the
1940s and has improved the outcome of diseases such as tuber-
culosis and HIV10–16. However, it is a challenge to combine drugs
that not only have high potency against the pathogen but also
constrain the evolution of resistance, owing to our limiting
understanding of phenomena such as positive and negative drug
interactions (synergy and antagonism), as well as collateral
resistance and sensitivity17–19.
Numerous studies have examined how drug pairs can be
rationally designed. Previously, we and others have shown that
antibiotic combinations, in which the evolution of resistance to
one of the drugs leads to collateral sensitivity against the other
drug, effectively constrain the evolution of adaptive resistance in
Escherichia coli20, Staphylococcus aureus21,22 and Pseudomonas
aeruginosa23). Such studies motivated the development of
mathematical24 and computational models, such as ﬂux balance
analysis25 and ﬁtness landscape analysis of the evolutionary
potential of resistance26,27, which may guide in the development
of rationally designed drug combinations.
A common approach for studying resistance evolution and
rational drug design is to use adaptive evolution to identify
mutations conferring increased antibiotic resistance. Such studies
have led to the identiﬁcation of drug combination regimens
proposed to limit resistance evolution. However, this effect will
often depend on the nature of the interaction between the two
drugs and the targeted organism17,18,28,29. Furthermore, adaptive
resistance evolution does not consider the effect of horizontally
transferred genes, which constitute a major source of antibiotic
resistance for many pathogens30 and therefore are important to
study in relation to the efﬁcacy of drug combinations1,9. Some of
the studies that have been performed on horizontally transferred
genes aimed to quantify and predict the resistance evolution by
applying methods such as directed evolution using error-prone
PCR31,32, as well as adaptive evolution methods33–36. As an
example, treatment strategies that apply a selective pressure to
revert extended-spectrum-resistant genotypes of TEM β-
lactamases back to the Wild Type (WT) state have been pro-
posed by a data-driven model based on the ﬁtness costs of speciﬁc
resistance gene variants37.
Another way to study resistance evolution and to apply rational
drug design of horizontally transferred resistance genes is to
elucidate collateral sensitivity patterns by using a random muta-
genesis approach. The beneﬁt of using a random mutagenesis
approach to study evolution of horizontally transferred genes is
threefold: (1) It is an effective way of mimicking the evolutionary
process assuming that one mutation is present in each clone. (2)
A large library can easily be screened on various antibiotics. (3)
Traditional adaptive laboratory evolution methods are not always
suitable to study evolution of single horizontally transferred genes
due to the potential appearance of mutations in the host genome
that confer to increased resistance towards the speciﬁc
antibiotic38.
We use this method to study resistance evolution in the hor-
izontally transferred β-lactamase gene blaCTX-M-15, which repre-
sents the most common variant of the large CTX-M family of
extended-spectrum β-lactamases (ESBLs). blaCTX-M-15 is globally
disseminated and represents a substantial challenge in the treat-
ment of multidrug-resistant E. coli infections39,40. Bacteria har-
bouring CTX-M-15 are highly resistant to β-lactams, including
penicillins and cephalosporins41. However, they are commonly
susceptible to the β-lactam drugs: mecillinam, meropenem, and
piperacillin in combination with the β-lactamase inhibitor tazo-
bactam (piperacillin–tazobactam) (Supplementary Table 1)42.
Here we examine whether single mutations in the blaCTX-M-15
gene will provide increased resistance towards any of these drugs
and elucidate how collateral sensitivity can be exploited to pro-
pose drug combinations that constrain the resistance evolution of
blaCTX-M-15. We ﬁnd three single mutations that increase either
mecillinam or piperacillin resistance, while simultaneously
decreasing cephalosporin resistance. We verify in vitro and in
mice the effect of the drug combination mecillinam and cefo-
taxime as effective in eliminating both the CTX-M-15WT and the
resistant mutant. Based on this, we propose that a drug combi-
nation of mecillinam and cefotaxime can restrain resistance
evolution in CTX-M-15, and we elucidate how collateral sensi-
tivity patterns of horizontally transferred genes can be exploited
for rational design of antibiotic combinations.
Results
Discovery of three highly resistant CTX-M-15 mutants. To
examine whether any single mutations of the blaCTX-M-15 gene
could lead to increased resistance against the β-lactam drugs
mecillinam and meropenem or the β-lactam-inhibitor combina-
tion piperacillin–tazobactam, we generated a library of blaCTX-M-15
mutants using error-prone PCR. The library was transformed
into E. coli TOP10 and the transformation was selected on plates
containing different concentrations of the tested drugs, separately.
The cephalosporin ceftazidime, an antibiotic to which CTX-M-15
confers high resistance, was used as a positive control. Deep
sequencing of the blaCTX-M-15 library was performed for each
selection plate (colony-forming unit (CFU) count is in Supple-
mentary Tables 2 and 3). Sequencing of the library plated on
Lysogeny Broth (LB) medium without antibiotics was performed
to assess the background mutation distribution (Supplementary
Tables 2 and 3). To detect mutants that had gained both low- and
high-level resistance, screening was performed at concentrations
below and above the minimal inhibitory concentration (MIC) of
the antibiotics tested (0.5–4 × MIC, Table 1 in Methods)
(Fig. 1a–c). We estimate an average coverage of each possible
mutation in the blaCTX-M-15 library to be 280-fold (Methods).
Three highly resistant mutants were found: two on the
piperacillin–tazobactam selection plate (CTX-M-15S133G and
CTX-M-15G239S) and one on the mecillinam plate (CTX-M-
15N135D). The frequency of these mutants within the total
population (referred to as the total population frequency) was
highest on the higher-concentration selection plates, indicating that
they have a selective advantage over less resistant clones.
Speciﬁcally, the mutants CTX-M-15S133G and CTX-M-15G239S were
identiﬁed with a total population frequency of 25% and 16%,
respectively, on the 4 × MIC piperacillin–tazobactam plates, and the
CTX-M-15N135D mutant was identiﬁed with a total population
frequency of 52% on the 4 × MIC mecillinam selection plates. In
addition, a synonymous mutation, assumed to be linked to one of
the CTX-M-15N135D mutants, was observed at position 91 with a
frequency of 9% at 4 × MIC of mecillinam (Fig. 1a and b).
None of the clones showed increased resistance against
meropenem (Fig. 1c). In addition, we screened the library on
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the β-lactam-inhibitor combination amoxicillin–clavulanic acid,
which CTX-M-15 provides resistance above the clinical break-
point of 8 µg/ml (deﬁned by the European Committee on
Antimicrobial Susceptibility Testing (EUCAST)). The MIC of
CTX-M-15WT is 14 µg/ml (Supplementary Table 1). We did this
to determine whether it was possible for CTX-M-15 to increase
resistance against this drug combination with only one mutation.
One mutant, which was selected on amoxicillin–clavulanic acid
(32 µg/ml), CTX-M-15G242D, showed increased resistance against
amoxicillin–clavulanic acid. As CTX-M-15WT already provides
resistance against this drug, the mutation has limited impact
in vivo. Therefore, this mutant was not included in subsequent
experiments.
By visualizing the resistance mutations on a three-dimensional
structure of the CTX-M-15 enzyme bound to the cephalosporin
cefotaxime (Fig. 1d), it was clear that all amino acid substitutions
were clustered in the active site of the enzyme and therefore were
likely to change the binding afﬁnity for the three investigated
drugs as well as for cephalosporins.
CTX-M-15 mutants exhibit collateral sensitivity to cephalos-
porins. To characterize the changes in antibiotic susceptibility of
the mutants, as well as possible epistatic interactions between
them, single and double mutants were constructed and expressed
in E. coli TOP10. Antibiotic susceptibility was determined for a
panel of β-lactam antibiotics towards which CTX-M-15WT con-
fers resistance: amoxicillin–clavulanic acid and cefotaxime, as well
as some β-lactams to which CTX-M-15WT does not confer
resistance: mecillinam alone and in combination with the inhi-
bitors clavulanic acid or tazobactam, meropenem, and piperacillin
alone, and in combination with tazobactam. Mecillinam was
tested together with the inhibitors to test for drug synergy or
antagonism. The MIC fold changes were calculated for each drug
and each mutant relative to CTX-M-15WT (Fig. 2a and b).
The single mutant selected on mecillinam, CTX-M-15N135D,
showed a 50-fold increase in mecillinam MIC compared with
CTX-M-15WT (from 0.3 µg/ml to 15 µg/ml), thereby exceeding
the clinical breakpoint of 8 µg/ml (as deﬁned by EUCAST)
(Supplementary Table 1). When exposed to mecillinam in
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Fig. 1 Frequency of CTX-M-15 clones selected on antibiotics and position of mutations. A blaCTX-M-15 gene mutant library obtained by error-prone PCR
was grown on different antibiotic concentrations (0.5–4 × minimal inhibitory concentration (MIC)), the resulting clones were sequenced, and the
percentage of reads for each SNP is shown for: mecillinam (a), piperacillin–tazobactam (b), and meropenem (c). The CTX-M-15 wild-type (CTX-M-15 WT)
MIC for mecillinam is 0.25 µg/ml, for piperacillin–tazobactam is 16 µg/ml, and for meropenem is 0.06 µg/ml. d A 3D structure of the CTX-M-15-binding
site with cefotaxime (orange) (PDB: 5FAP [https://www.rcsb.org/structure/5FAP]). Mutations providing high resistance against mecillinam: N135D
(orange), against piperacillin–tazobactam: S133G and G239S (green), and amoxicillin–clavulanic acid (blue). Amino acid (AA) letters with uncharged side
chains are written in black and negatively charged side chains in red
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combination with one of the β-lactamase inhibitors, clavulanic
acid or tazobactam, this mutant showed a smaller increase in
resistance compared with exposure to mecillinam alone (2.6- and
4.8-fold, respectively), despite the concentration of mecillinam
being the same in all three experiments (0.25 µg/ml at 1 × MIC
for CTX-M-15WT). The single mutants CTX-M-15S133G and
CTX-M-15G239S, which were initially selected on
piperacillin–tazobactam, showed an increase in the MIC of
piperacillin–tazobactam by 8- and 4.5-fold (corresponding to 13
µg/ml and 7.3 µg/ml), compared with CTX-M-15WT (1.6 µg/ml)
(Fig. 2a), thereby exceeding or approaching the clinical break-
point for piperacillin–tazobactam of 8 µg/ml (as deﬁned by
EUCAST) (Supplementary Table 1).
Interestingly, for all double mutants (except CTX-M-15S133G-
N135D) the MIC decreased to the levels of CTX-M-15WT falling
below the clinical breakpoints for all the tested drugs. This result
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Fig. 2 Fold change of re-constructed mutants and MIC values for different CTX-M-15 carrying strains. a Fold change of the MIC of the indicated antibiotics
for E. coli TOP10 expressing the indicated single mutants of CTX-M-15. Substantial collateral sensitivity and resistance results from individual mutants
selected in speciﬁc antibiotics. b Fold change of the MIC of the indicated antibiotics for E. coli TOP10 expressing double mutants of CTX-M-15. Negative
epistasis is observed for all double mutants except CTX-M-15S133G_N135D towards piperacillin–tazobactam. Fold changes for single and double mutants
are in relation to the MIC values of E. coli TOP10 expressing CTX-M-15WT. c The MIC was determined for the mecillinam-resistant mutant CTX-M-
15N135D against mecillinam and three different cephalosporins: cefuroxime (second generation), cefotaxime (third generation), and cefepime (fourth
generation). Two different strains were used as wild-type (WT) controls of CTX-M-15: E. coli MG1655 and a clinical E. coli ESBL strain, ST131. E. coli MG1655
was used for expression of CTX-M-15N135D. Blue bars indicate MIC values above the clinical breakpoint (as deﬁned by the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) (Supplementary Table 1). AmxCla, Amoxicillin–clavulanic acid; Ctx, cefotaxime; Mec, mecillinam; MecCla,
mecillinam–clavulanic acid; MecTzb, mecillinam–tazobactam; Mer, meropenem; Pip, piperacillin; PipTzb, piperacillin–tazobactam
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suggests the presence of negative epistasis between the mutations
G239S and S133G or N135D. The CTX-M-15S133G-N135D double
mutant had reduced resistance towards mecillinam compared
with the mecillinam-selected CTX-M-15N135D single mutant but
higher than that of the piperacillin–tazobactam-selected CTX-M-
15S133G and CTX-M-15WT. In addition, CTX-M-15S133G-N135D
showed increased resistance against piperacillin–tazobactam
compared with CTX-M-15N135D, to a level comparable to that
of the CTX-M-15S133G single mutant (Fig. 2b).
Collateral sensitivity to the cephalosporin cefotaxime was
observed for all constructed single and double mutants. The
cefotaxime MIC decreased from 23 µg/ml to < 2 µg/ml in all cases,
which is below the clinical breakpoint of 2 µg/ml (as deﬁned by
EUCAST) (Supplementary Table 1).
Based on this data we wanted to examine whether the CTX-M-
15N135D mutant had completely lost the ability to hydrolyse
cephalosporins. As controls to test whether resistance levels in E.
coli TOP10 cells were comparable to that of WT strains
expressing CTX-M-15, we used E. coli MG1655 (K12) trans-
formed with the plasmid (pZS3-CTX-M-15WT) and a clinical E.
coli ESBL strain, Ec35 (ST131), which carries the blaCTX-M-15 WT
resistance gene. Both strains showed high susceptibility to
mecillinam and high resistance to all tested cephalosporins:
cefuroxime (second generation), cefotaxime (third generation),
and cefepime (fourth generation). In contrast, CTX-M-15N135D-
expressing E. coli MG1655 hydrolysed the three cephalosporins at
low levels as reﬂected by the MICs, yet it showed high resistance
towards mecillinam as expected (Fig. 2c). To ensure that the
differences in susceptibilities between CTX-M-15WT and the
CTX-M-15N135D mutant were not caused by differences in ﬁtness,
we measured the exponential growth rates for E. coli MG1655
(pCTX-M-15N135D) and E. coli MG1655 (pCTX-M-15WT). These
strains had similar growth rates (Fig. 3a). These results
demonstrate the occurrence of collateral sensitivity interactions
within the CTX-M-15 gene between either
piperacillin–tazobactam or mecillinam and cephalosporin class
drugs.
Mecillinam with cefotaxime selects against resistant mutants.
Based on the observed collateral sensitivity patterns, we hypo-
thesized that a combination of a cephalosporin and either
mecillinam or piperacillin–tazobactam could prevent the one-step
evolution event leading to mecillinam or piperacillin–tazobactam
resistance. To examine this idea, we investigated the combination
of mecillinam and the cephalosporin cefotaxime. Mecillinam was
chosen over piperacillin–tazobactam for several reasons; it is an
important drug for treating urinary tract infections (mostly in
Scandinavia); mecillinam works without addition of an inhibitor;
it can reach very high concentrations in the urine (> 200 mg/l),
which is desirable, as it is mainly used to treat urinary tract
infections; it is well tolerated; has a high absorption rate in the
intestine; a low occurrence of clinical resistance; and a minimal
effect on gut and vaginal microﬂora43.
To test whether any single mutants could confer resistance to
the combination of mecillinam and cefotaxime, the blaCTX-M-15
library was plated on agar plates containing both drugs. The
concentrations were chosen such that mecillinam would select
against CTX-M-15WT (4–16 × MIC for CTX-M-15WT) and
cefotaxime would select against mutants with decreased ability
to hydrolyse cefotaxime (1–4 × MIC for CTX-M-15N135D). Agar
plates containing only mecillinam (8 × MIC for CTX-M-15WT)
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were used as a positive control. To ensure the representation of all
possible CTX-M-15 variants, we plated approximately 6 × 107 cells
providing > 1000 × coverage of possible mutants (see Methods). A
few colonies grew on the combination plates but none were
recovered after re-streaking, indicating that these colonies did not
harbour genetically stable resistance to the drug combination. Ten
colonies from the mecillinam-only selection plates were Sanger
sequenced and all were veriﬁed to be CTX-M-15N135D single
mutants. These results suggest that although mecillinam resis-
tance can be effectively selected from the library, no single-
nucleotide polyorphisms (SNPs) in the library provided com-
bined mecillinam and cephalosporin resistance.
As CTX-M-15N135D was the mutant in the library showing the
highest increase in mecillinam resistance, we wanted to explore
how this mutant would grow in various concentrations of both
mecillinam and cefotaxime. For this purpose, a two-dimensional
(2D) competition experiment was performed with CTX-M-15WT
and CTX-M-15N135D mixed in 1:1 ratio. This was performed to
expose the the mecillinam-resistant mutant to a concentration
gradient of the two drugs, having increased mecillinam
concentrations on one axis and increased cefotaxime concentra-
tions on the other axis. To be able to count the number of mutant
cells using ﬂuorescence-activated cell sorting (FACS), a strain of
E. coli MG1655 was labelled with gfp (galK::gfp) and pZS3-CTX-
M-15N135D was introduced. The two E. coli MG1655 strains were
mixed at a 1:1 ratio and were grown for 5 h in a 2D gradient of
mecillinam and cefotaxime (Fig. 3b). The frequency of both
strains was assessed using ﬂow cytometry and compared with the
total number of cells in the respective well. We found that
although the CTX-M-15WT carrying strain was highly enriched at
high cefotaxime concentrations and the CTX-M-15N135D mutant
at high mecillinam concentrations, the number of cells able to
grow as both drug concentrations were increased was substan-
tially reduced (Fig. 3b). These ﬁndings were conﬁrmed in a
repeated experiment with switched background genotypes
(labelling of E. coli MG1655 (galK::gfp) (pZS3-CTX-M-15WT)
(Supplementary Fig. 1). This and the previous experiment show
how collateral sensitivity between mecillinam and a cephalos-
porin limits the growth of mecillinam-resistant CTX-M-15
mutants.
Mecillinam and cefotaxime inhibits growth of CTX-M-15 in
mice. Our in vitro results showed that a drug combination of
mecillinam and cefotaxime could eliminate both cephalosporin-
resistant bacteria harbouring CTX-M-15WT and mecillinam-
resistant bacteria harbouring the mutant CTX-M-15N135D,
thereby limiting the evolutionary potential of CTX-M-15. To test
whether this would also be applicable in vivo, we used a well-
established peritonitis mouse model system used to evaluate
in vivo survival of the bacterium Salmonella enterica Typhi-
murium strain LT2 by assessing CFU counts in the liver and
spleen. Salmonella was chosen due to its ability to spread to
internal tissues making in possible to evaluate the level of infec-
tion based on CFU counts in the organs44. Mice were injected
with bacteria carrying either CTX-M-15WT or the mecillinam-
resistant CTX-M-15N135D variant on a plasmid. The infected mice
were treated with mecillinam, cefotaxime, or a combination of
mecillinam and cefotaxime (mecillinam, 100mg/kg/day and
cefotaxime, 150 mg/kg/day).
Mice infected with the strain expressing CTX-M-15WT and
treated with mecillinam or a combination of mecillinam and
cefotaxime had signiﬁcantly lower bacterial counts in the liver
than control mice and mice treated with cefotaxime. Conversely,
mice infected with the strain expressing CTX-M-15N135D and
treated with cefotaxime or a combination of cefotaxime and
mecillinam had signiﬁcantly lower counts in the liver than control
mice and mice treated with mecillinam (Fig. 4a and b). CFU per
gram counts were also evaluated in the spleen and showed similar
results (Supplementary Fig. 2).
Importantly, the combination of mecillinam and cefotaxime
signiﬁcantly reduced the load of bacteria expressing either CTX-
M-15WT or CTX-M-15N135D in both investigated organs. These
data highlight the fact that the drug combination is effective in an
animal infection model, strongly suggesting that the administra-
tion of mecillinam and cefotaxime together could potentially limit
the evolution of the blaCTX-M-15 gene, limiting both cephalos-
porin- and mecillinam-resistant variants.
Discussion
In this study, we describe how collateral sensitivity patterns can
arise in a horizontally transferred β-lactamase gene in response to
resistance evolution. In particular, we ﬁnd that CTX-M-15 var-
iants that have increased resistance towards antibiotics, including
mecillinam, become collaterally sensitive to cephalopsorins. Based
on these data we demonstrate in vitro that combination treatment
with mecillinam and cefotaxime limits the ability of CTX-M-15 to
counteract the antibiotics due to the reciprocal collateral sensi-
tivity. Furthermore, we show that this drug combination can
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Fig. 4 Bacterial counts from mice infected with CTX-M-15WT or CTX-M-15N135D after treatment. Mice infected via intraperitoneal injection with S.
typhimurium expressing either CTX-M-15WT strain (a) or the mutant strain carrying CTX-M-15N135D (b) were treated with mecillinam (Mec), cefotaxime
(Ctx), or a combination of the two. PBS was used as a negative control. Bacterial counts of liver tissue (colony-forming units (CFU)/g) are shown (four
mice per group). Inoculum size was 1.5 × 105 CFU/mouse. ns: not signiﬁcant; *p < 0.05; **p < 0.01. Horizontal bold line denotes the median. Statistical
analysis was performed using unpaired Student’s t-test. Symbols surrounded by a black border represent counts on plates with < 20 CFU (in those cases,
statistical signiﬁcance was calculated assuming 20 CFU/plate). One mouse infected with the mutant CTX-M-15N135D and treated with mecillinam in
combination with cefotaxime cleared the infection. Data from this mouse are not plotted
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overcome infections with strains expressing either of the two
resistant variants of CTX-M-15, suggesting that the antibiotic
combination could have a clinical utility.
Traditionally, collateral sensitivity interactions have been
identiﬁed for chromosomal mutations using adaptive evolu-
tion9,20,22,23,45,46; yet, for horizontally acquired resistance genes
collateral sensitivity has not been studied in-depth. One study
found that amoxicillin–clavulanic acid adapted clones of E. coli
expressing β-lactamases from the CTX-M family showed antag-
onistic pleiotropic effects between the β-lactam-inhibitor combi-
nations piperacillin–tazobactam and amoxicillin–clavulanic acid,
and several drugs within the cephalosporin class33. However,
studying the evolutionary potential of a single acquired resistance
gene using adaptive evolution can be challenging. For some
antibiotics, including mecillinam, several chromosomal mutations
in E. coli can lead to increased resistance. However, these muta-
tions often incur increased ﬁtness cost making them less clinically
relevant47. Therefore, using traditional adaptive evolution to
study mecillinam resistance conferred by horizontally transferred
genes in E. coli is not feasible. To address this issue we examined
the evolutionary potential and constraints of CTX-M-15 adaptive
change using directed evolution, which enables the study of a
single gene of interest without confounding factors resulting from
host genome mutations in response to antibiotic exposure31,32.
This laboratory approach is a simpliﬁcation compared with the
clinical setting in which both chromosomal mutations and
acquired resistance genes contribute to resistance phenotypes in
response to antibiotic gradients in space and time. However, we
consider the approach relevant, as it allows an assessment of the
evolutionary potential of acquired resistance genes under differ-
ent selective conditions.
The CTX-M-15 enzyme proved to be very sensitive to muta-
tions in the active site, leading to loss of cephalosporin resistance,
which might explain the low level of mecillinam and
piperacillin–tazobactam resistance generally observed within the
CTX-M-1 and CTX-M-9 families33,48. Interestingly, this type of
mutually exclusive resistance patterns has also been observed for
other resistance genes, e.g., aminoglycoside-modifying enzymes49.
This indicates that it is difﬁcult for antibiotic resistance enzymes
to evolve an active site that efﬁciently hydrolyses several distinct
types of drugs. The prevalence of such collateral sensitivity
interactions strongly warrants further research into how acquired
antibiotic resistance genes can be countered using drug combi-
nation therapy. Even exploiting the differential sensitivity of
related drugs from the same class could be a promising avenue for
drug combination therapy. Although the screening approach
deployed in this study could be used to identify new drug com-
binations, structural studies at molecular resolution of acquired
resistance genes could also help to elucidate their evolutionary
potential and adaptive constraints.
In conclusion, antibiotic combinations, even of related drugs,
show potential for counteracting the rapidly developing problem
of acquired antibiotic resistance. In-depth studies of new drug
combinations should be initiated both in the laboratory as well as
in the clinic, speciﬁcally for dealing with the global problems of
ESBLs. In particular, the drug combination of mecillinam and
cefotaxime warrants further attention for management of urinary
tract infections (UTIs) caused by ESBLs. Both due to the high
efﬁcacy of mecillinam in treating UTIs and because the levels of
mecillinam resistance in the clinic is still low42. Future in vivo and
human studies should illuminate whether this antibiotic combi-
nation approach based on collateral sensitivity could help address
the issue of antibiotic resistance in the clinic. The approach
employed in this study may extend the use of existing or novel
antibiotics and help to predict the evolutionary directions of
emerging resistance genes.
Methods
Construction of the blaCTX-M-15 mutant library. As a backbone for the blaCTX-M-
15 mutant library we used the low-copy number kanamycin-resistant plasmid
pZS24 (region 678–3984) from the pZ-vector system (http://www.expressys.com/
main_vectors.html). A geneblock (IDT) containing the β-lactamase promoter,
terminator, and multiple cloning sites was blunt-end cloned into the backbone and
the resulting plasmid was named pZS3. Solution was treated with DnpI (Ther-
moFisher #FD1703) and puriﬁed using QIAquick PCR puriﬁcation kit (Qiagen).
The blaCTX-M-15 gene was ampliﬁed from a plasmid isolated from an E. coli clinical
isolate using the primers CTX-M-15-F and CTX-M-15-R (primer sequence in
Supplementary Table 4). The primers contained restriction enzyme tails for SalI
and HindIII also present in the geneblock. pZS3 and puriﬁed CTX-M-15 PCR
product (PCR puriﬁcation kit, Qiagen) were mixed with each restriction enzyme
(Thermo Fisher #FD0644 and #FD0505) + Fast Digest Buffer 10 × (ThermoFisher
#B64) according to manufacturer’s protocol. Solution was puriﬁed with QIAquick
PCR puriﬁcation kit (Qiagen). The two products were ligated using T4 DNA ligase
and ligase buffer (ThermoFisher #EL0011). The resulting plasmid was named
pSZ3-CTX-M-15WT. To create a backbone that could be used for error-prone PCR
and where negative selection against the blaCTX-M-15 WT gene could be performed,
we used the plasmid pJET containing an ampicillin resistance gene (ThermoFisher
#K1231). bla CTX-M-15 was ampliﬁed from pZS3-CTX-M-15WT using the primers
pZ-insert-F and CM-insert-R pZS. DNA ligase and T4 DNA ligase buffer (Ther-
moFisher #EL0011) were used during the cloning procedures. This plasmid was
named pJET-CTX-M-15WT. Then, error-prone PCR was performed with the
Genemorph II random mutagenesis kit (Agilent Technologies #200550) run on the
blaCTX-M-15 WT gene with pJET-CTX-M-15WT as a template (500 ng of target
DNA) following the manufacturer’s protocol using the primers gblok-CTX-M-15-F
and gblok-CTX-M-15-R. The PCR product run on an agarose gel and the band was
cut and puriﬁed with a gel-extraction kit (Qiagen). The error-prone PCR product
was then used as a template for PCR with primers that added restriction enzyme
tails (AscI-CTX-M-15-F and PmeI-CTX-M-15-R) during 20 PCR cycles. The PCR
product was run on an agarose gel and puriﬁed with the Gel-Extraction Kit
(Qiagen). To amplify a backbone for the mutant CTX-M-15 library, we used pZS3
as a template and primers containing restriction enzyme tails for AscI and PmeI:
PmeI-Ancestral-pZS3-F and AscI-Ancestral-pZS3-R. Both products were cut
(ThermoFisher enzymes: #ER1891 and #ER1341) and puriﬁed using QIAquick
PCR puriﬁcation kit (Qiagen), and dephosporylated using 1 µl Phosphatase fast
digest (ThermoFisher #EF0654) and puriﬁed with QIAquick PCR puriﬁcation
(Qiagen). Ligation was performed using vector:insert ratio of 1:10 and ligated using
T4 DNA ligase and ligase buffer (ThermoFisher #EL0011). The product resulting
from this ligation, containing the blaCTX-M-15 SNP library named pZS3-CTX-M-
15-Mut2Vol2, was transformed into electrocompetent E. coli TOP10 (Thermo-
Fisher #C66455) and selected on kanamycin (50 µg/ml). The second library was
constructed similarly to the ﬁrst library, except that 8 instead of 20 cycles were run
on the error-prone PCR product with primers containing restriction enzyme tails.
The second library was named pZS3-CTX-M-15-Mut6. The complete sequence of
the blaCTX-M-15 gene and the β-lactamase promoter can be found in Supplementary
Data 1.
Estimation of the library coverage. The blaCTX-M-15 gene contains 875 bp, which
leaves 875 × 3= 2625 total possible SNPs of the gene. In total, 1153 blaCTX-M-15
SNPs (43% of the 2625 possible SNPs) were detected after sequencing, with fre-
quencies above the Illumina sequencing error rate, which is estimated to be ~0.1%50.
In total, the two libraries comprised 2 × 106 clones based on an average CFU count
from dilution count assay. Based on Sanger sequencing of 24 colonies, the average
mutation rate was estimated to be 0.957 (8 with 0 mutations, 10 with 1 mutation, 4
with 2 mutations and 1 with 4 mutations). Using the PEDEL programme that
estimates the diversity in error-prone PCR libraries, http://guinevere.otago.ac.nz/
cgi-bin/aef/pedel.stats.pl51, the estimated number of mutants with exactly one
mutation in both libraries was found to be 7.351 × 105. This renders a SNP coverage
of 735,100/2625= 280, assuming equal distribution of all SNPs.
Screening of the mutant library on a variety of antibiotics. The CTX-M-15-
Mut2Vol2 library was screened on LB agar plates containing the antibiotics shown
in the Table 1. CTX-M-15WT was screened on the same plates as control. The
second library Mut6 was screened in the same way and on additional antibiotics:
ertapenem, amoxicillin–clavulanic acid, and mecillinam in combination with the
two inhibitors tazobactam and clavulanic acid (SM).
To ensure that all SNPs were present on each plate at least once, the coupon
collector problem52 was applied, as follows:
M ¼ N logðNÞ
logðPÞ ð1Þ
For P= 99.9%:
M ¼ 2625 logð2625Þ
logð0:999Þ ¼ 39:000 cells
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08529-y ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:618 | https://doi.org/10.1038/s41467-019-08529-y | www.nature.com/naturecommunications 7
where M is the number of cells on each plate, N is total SNPs and P is the
probability of obtaining all SNPs. The number of cells should be as low as possible
to avoid overgrowth but high enough to ensure the presence of all mutants with a
probability of 99.9%. Assuming an error rate of 10/24 × 100= 42% of all cells to
contain SNPs (based on Sanger sequencing), at least 39,000 cells × (100/42)=
92,857 cells should be plated on each plate to obtain 99.9% of all SNPs in the
library. In total, we plated ~6 × 107 cells for a very high probability of plating all
clones. One hundred microlitres were plated on each plate, the mutant library in
four replicates and CTX-M-15WT in two replicates.
Next-generation sequencing. Next-generation sequencing (NGS) was performed
using the MiSeq System from Illumina for the 0.5–4 × MIC libraries selected on
either piperacillin–tazobactam or mecillinam, the single library selected on 0.5 ×
MIC meropenem and one library grown on LB agar without antibiotics used as
control (for the library CTX-M-15-Mut2Vol2). The library CTX-M-15-Mut6 was
screened in the same way. DNA was isolated by adding 2 ml of 0.9% NaCl to each
plate and scraping off the colonies. Two hundred microlitres of the solution were
centrifuged for 4 min. Plasmid puriﬁcation was performed with the QIAprep Spin
Miniprep Kit (Qiagen) according to the manufacturer’s recommendations. The
Nextera XT DNA kit (Illumina) was used for library preparation. CLC Genomic
Workbench was used to transform the Illumina sequencing data. A cutoff SNP
frequency value of 0.1% was used, owing to the Illumina sequencing error rate50.
Construction of single and double CTX-M-15 mutants. Primers introducing the
mutations A > G at position 397 (S133G), A > G at position 403 (N135D) and G >
A at position 715 (G239S) were used to amplify the blaCTX-M-15 WT gene using
pJET-CTX-M-15WT as a template (primer sequences in Supplementary Table 4).
To amplify a backbone for the mutants, we used pZS3 as a template, and primers
Ancestral-pZS3-F and Ancestral-pZS3-R. PCR product was DnpI treated (Ther-
moFisher #FD1703) and puriﬁed using QIAquick PCR puriﬁcation kit (Qiagen).
The amplicon was blunt-end cloned using T4 DNA ligase and ligase buffer
(ThermoFisher #EL0011). Ligation solution was puriﬁed with PCR cleanup (A&A
Technologies). Each of the resulting plasmids pZS3-CTX-M-15N135D, pZS3-CTX-
M-15S133G and pZS3-CTX-M-15G239S were transformed into electrocompetent E.
coli TOP10 (ThermoFisher #C66455). Mutations were veriﬁed with Sanger
sequencing. The double mutants S133G-G239S and S133G-N135D were con-
structed using blaCTX-M-15 S133G as template DNA for PCR with primers introdu-
cing the mutations G239S and N135D, respectively. The double mutant N135D-
G239S was constructed using blaCTX-M-15 N135D as template. Same cloning proce-
dure was performed as for the single mutants.
MIC tests for single and double CTX-M-15 mutants. MIC tests were performed
for each of the six pZS3-CTX-M-15 mutants, the pZS3-CTX-M-15WT and pZS3 as
a control. MHBII media was used for MIC tests (Sigma). Each strain was inocu-
lated separately in kanamycin-MHBII media (10 μg/ml) and grown overnight to a
cell density of ~1010 CFU/ml. The cells were diluted in MHBII media to a con-
centration of 108 CFU/ml. Ninety-six deep-well plates were used to prepare the
antibiotic concentrations and 150 μl were copied into ﬁve 96-well plates. One
microlitre of the 108 dilutions was inoculated into a twofold antibiotic gradient in
liquid media in ﬁve technical replicates and grown with shaking at 37 °C overnight.
Growth was measured using spectrophotometry. The MIC values were determined
as the concentration at which cell growth was 100% inhibited (OD corresponds to
pZS3). The following antibiotics and concentrations (lowest to highest of twofold
dilution assay) were used: mecillinam (Sigma, CASRN: 32887-01-7, assigned by the
Chemical Abstracts Service) (0.0156–4 μg/ml), amoxicillin trihydrate (TCI Che-
micals, CASRN:61336-70-7), potassium clavulanate (Fluka Analytic,
CASRN:61177-45-5), cefotaxime sodium salt (Sigma, CASRN:64485-93-4), mer-
openem (Astra-Zeneca, CASRN:119478-56-7) (0.00375–0.96 μg/ml), piperacillin
sodium salt (Sigma, CASRN:59703-84-3) (16–4096 μg/ml) and tazobactam (TCI
Chemicals, CASNR:89786-04-9). Combinations of inhibitor and antibiotic were
mixed according to the clinical usage of piperacillin–tazobactam (8:1) (total con-
centration of twofold dilutions: 0.25–64 μg/ml) and amoxicillin–clavulanic acid
(4:1) (total concentration of twofold dilution: 0.5–128 μg/ml). The concentrations
of tazobactam and clavulanic acid with mecillinam are consistent with the inhibitor
concentrations in piperacillin–tazobactam and amoxicillin–clavulanic acid.
Mecillinam–tazobactam= 1:2 (0.0156/0.0275–4/7.04 μg/ml) and
mecillinam–clavulanic acid= 1:6.4 (0.0156/0.1–4/25.6 μg/ml). E. coli MG1655 was
transformed with the plasmid pZS3-CTX-M-15WT and MIC tests were performed
against mecillinam and three different cephalosporins: cefuroxime (Sigma,
CASRN:56238-63-2), cefotaxime and cefepime (CASRN:88040-23-7) (fourth gen-
eration). The clinical E. coli ESBL strain ST131 carrying CTX-M-15 was used to
validate similar resistance levels between this strain, E. coli MG1655 and E. coli
TOP10.
Growth experiment in a gradient of mecillinam vs. cefotaxime. E. coli MG1655
(pZS3-CTX-M-15WT) was mixed with E. coli MG1655 galK::gfp (pZS3-CTX-M-
15N135D) (constructed by inserting gfp within the galK gene) in a 1:1 ratio and
grown in a 2D gradient of mecillinam vs. cefotaxime. Cells were grown for 5 h at
37 °C with shaking in LB medium and 10 µl of the cell suspension was inoculated
into each well (ﬁve technical replicates were used). The cefotaxime concentrations
were 0.02–2 µg/ml and mecillinam concentration was 0.03–4 µg/ml. The well with
the highest concentration of antibiotics corresponded to CTX-M-15WT 4 × MIC for
mecillinam and CTX-M-15N135D 2 × MIC for cefotaxime. The experiment was
performed again with E. coli MG1655 galK::gfp (pZS3-CTX-M-15WT) against E.
coli MG1655 (pZS3-CTX-M-15N135D), to ensure that green ﬂuorescent protein
expression did not affect the experimental outcome. Cells were counted by FACS
sorting.
Growth rate experiment. E. coli MG1655 (pZS3-CTX-M-15WT) and E. coli
MG1655 (pZS3-CTX-M-15N135D) were grown overnight in 96-well plates in 200 µl
LB with kanamycin (50 μg/ml), using six biological replicates. A new 96-well plate
with 200 µl LB without antibiotic was used to inoculate 1 µl of the overnight
cultures. The negative control wells contained no cells. The plate was covered with
Breath-Easy seal and a kinetic run was performed in a plate reader (BioTek,
Elx808). Linear regression was performed on the data points from the exponential
phase with Microsoft Excel.
Mouse study. Fresh overnight cultures of S. typhimurium strain LT2 carrying
pZS3-CTX-M-15WT or pZS3-CTX-M-15N135D were grown in LB medium at 37 °C
with shaking at 190 r.p.m. until saturation. The cells were washed three times in
sterile phosphate-buffered saline (PBS). Female BALB/c mice (6 weeks old) were
used (Charles River Laboratories). The mice were injected intraperitoneally with
100 µl of ~106 CFU/ml bacteria. The inoculum size was quantiﬁed by plating
appropriate tenfold dilutions on LB agar plates supplemented with kanamycin
(50 μg/ml) to select for the pZS3 plasmid. Thirty minutes post infection, the mice
were divided into four treatment groups (four mice/group) and treated intraper-
itoneally (50 µl) with PBS, mecillinam (100 mg/kg/day), cefotaxime (150 mg/kg/
day) or a combination of both drugs. Antibiotics were administered in two half-
daily doses for 36 h. Two days after the ﬁrst treatment dose, the mice were killed by
cervical dislocation. The spleens and livers were collected and homogenized cell
suspensions were prepared in PBS. Tenfold dilutions were spread on LB plates
supplemented with kanamycin, to determine the bacterial burden in mice. The
bacterial counts were normalized per gram of tissue (CFU/g). Uppsala Animal
Ethics Committee (permit no C154/14) approved all mouse experiments, which
were performed in accordance with national and institutional guidelines in the
Swedish National Veterinary Institute in Uppsala, Sweden.
Statistical analysis. The inhibitory concentration for CTX-M-15WT and con-
structed mutant strains were determined as the lowest drug concentration that
inhibited 100% growth compared with control based on A600 measurements
(IC100), using ﬁve replicates. Unpaired Student’s t-test was used for statistical
analysis of difference between mice groups based on CFU/g from the liver and
spleen, using four replicates (*p < 0.05, **p < 0.01). The coupons collector problem
was applied to calculate how many mutant library clones should be plated on a
selective plate to have all clones represented with 99.9% probability, using
equation 1.
Construction of a second CTX-M-15 library. The second library was made using
the error-prone PCR library also used to construct CTX-M-15-Mut2Vol2. The
method was identical to the construction of the ﬁrst library, except that 8 instead of
20 cycles were run with restriction enzyme tails when amplifying the error-prone
PCR. The second mutant library was plated on a non-selective LB plate and the
following antibiotics and antibiotic-inhibitor combinations piperacillin and tazo-
bactam, mecillinam, mecillinam–tazobactam, mecillinam–clavulanic acid, mer-
openem, ertapenem (Merck, CASRN: 1-9-1), amoxicillinclavulanic acid and
ceftazidime (TCI Chemicals, 72558-82-8) (negative control). NGS was then per-
formed on the growth results. The CTX-M-15-Mut6 library contained 895 unique
SNPs with a frequency of > 0.1%. In total, 1153 non-redundant SNPs were found in
the two combined libraries.
Table 1 Concentrations of antibiotics used for screening the
CTX-M-15 library
MIC PIP-
TZB
Mecillinam Meropenem Ceftazidime
0.5 4 0.125 0.03 —
0.75 8 0.1875 0.045 —
1 16 0.25 0.06 —
2 32 0.5 0.12 4
4 64 1 0.24 8
Concentrations are in µg/ml. PIP-TZB: piperacillin–tazobactam. Ceftazidime: positive control
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Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All relevant raw data are available from the authors upon request.
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